The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2024

Filed:

Apr. 23, 2019
Applicant:

Iomx Therapeutics Ag, Martinsried, DE;

Inventors:

Peter Sennhenn, Martinsried, DE;

Sebastian Meier-Ewert, Martinsried, DE;

Nisit Khandelwal, Martinsried, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 417/12 (2006.01); A61K 9/00 (2006.01); A61K 9/28 (2006.01); A61K 31/47 (2006.01); A61K 31/506 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07D 417/14 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07D 417/12 (2013.01); A61K 9/0053 (2013.01); A61K 9/2813 (2013.01); A61K 9/282 (2013.01); A61K 9/2853 (2013.01); A61K 9/2866 (2013.01); A61K 9/2893 (2013.01); A61K 31/47 (2013.01); A61K 31/506 (2013.01); A61K 39/3955 (2013.01); A61K 39/4636 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07D 417/14 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01);
Abstract

The invention relates to a kinase inhibitor, in particular an inhibitor of protein kinases including the protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or their mutants. Although structurally similar to dasatinib, the kinase inhibitor of the invention displays, eg functional and ADMET properties distinct to dasatinib. Also, the invention relates to pharmaceutical compositions that comprise the kinase inhibitor, including those formulated for oral administration, such as in unit dose form that comprise particular ranges or amounts of the kinase inhibitor. The kinase inhibitor or pharmaceutical composition may be used in the treatment of a proliferative disorder, such as a leukaemia or solid tumour. The kinase inhibitor or pharmaceutical composition may be used in a treatment regimen that corresponds to, is similar to or is distinct from that used with dasatinib for a corresponding disorder, and in particular may be used in a combination treatment regimen together with one or more additional therapeutic agents, such as immune-checkpoint inhibitors.


Find Patent Forward Citations

Loading…